Comparison of the SureX^® HPV genotyping test with the Digene Hybrid Capture^® 2 test in cervical cancer screening.

ABSTRACT:

Introduction

Cervical cancer, predominantly caused by high-risk human papillomavirus (HR-HPV) infections, is a critical public health issue. Effective screening is essential. This study compares the SureX^® HPV genotyping test, which detects 25 HPV types, with the widely used Digene Hybrid Capture^® 2 (HC2) test, which targets 13 HR-HPV types, to determine their effectiveness in cervical cancer screening among Chinese women.

Methods

From September to December 2016, women aged 21-64 years in Shanxi Province were screened for cervical cancer using both SureX^® HPV and HC2 tests. Women with abnormal cytology test would be referred for colposcopy and biopsied if necessary. Concordance rates and kappa coefficients were calculated to analyze the conco

SUBMITTER: Sun H 

PROVIDER: S-EPMC12328181 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature